Oncotarget

Reviews:

Hypoxia inducible factors in hepatocellular carcinoma

Chu Chen & Tao Lou _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:46691-46703. https://doi.org/10.18632/oncotarget.17358

Metrics: PDF 1168 views  |   HTML 4481 views  |   ?  


Abstract

Chu Chen1, Tao Lou1

1Department of Internal Medicine, Fourth Affiliated Hospital of Zhejiang University, School of Medicine, Yiwu, 322000, Zhejiang, China

Correspondence to:

Tao Lou, email: 05lcyxlt@zju.edu.cn

Keywords: liver cancer, hepatoma, HIF, hypoxia, therapy

Received: February 13, 2017     Accepted: April 04, 2017     Published: April 21, 2017

ABSTRACT

Hepatocellular carcinoma is one of the most prevalent and lethal cancers with limited therapeutic options. Pathogenesis of this disease involves tumor hypoxia and the activation of hypoxia inducible factors. In this review, we describe the current understanding of hypoxia signaling pathway and summarize the expression, function and target genes of hypoxia inducible factors in hepatocellular carcinoma. We also highlight the recent progress in hypoxia-targeted therapeutic strategies in hepatocellular carcinoma and discuss further the future efforts for the study of hypoxia and/or hypoxia inducible factors in this deadly disease.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17358